Therapeutic potential of oestrogen receptor ligands in development for osteoporosis

Bibliography

• Riggs BL, (Ed.), Raven Press, New York, USA (1988):333–358.
   Google Scholar
• BARZEL US: Estrogens in the prevention and treatment of postmenopausal osteoporosis: a review. Am. J. Med. (1988) 85:847–850.
   PubMed Web of Science ®Google Scholar
• GRODSTEIN F, STAMPFER MJ: The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog. Cardiovasc. Dis. (1995) 38:199–210.
   PubMed Web of Science ®Google Scholar
• BARRETT-CONNER E: Hormone replacement and cancer. Br. Med. Bull. (1992) 48:345–355.
   PubMed Web of Science ®Google Scholar
• CAULEY JA, LUCAS FL, KULLER FH, et al.: Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. JAMA (1996) 276:1404–1408.
   PubMed Web of Science ®Google Scholar
• COLDITZ GA, HANKINSON SE, HUNTER DJ, et al.: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J Med. (1995) 332:1589–1593.
   PubMed Web of Science ®Google Scholar
• Smith R (Ed.), Royal College of Physicians, London, UK (1990):199–208.
   Google Scholar
• GRAINGER DJ, METCALFE JC: Tamoxifen: teaching an old drug new tricks Nature Med. (1996) 2:381–385.
   Google Scholar
• YANG NN, VENUGOPALAN M, HARDIKAR S, et al: Identi-fication of an estrogen response element activated by metabolites of 1713-estradiol and raloxifene. Science (1996) 273:1222–1225.
   PubMed Web of Science ®Google Scholar
• KE HZ, SIMMONNS HA, PIRIES CM, et al.: Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology (1995) 136:2435–2441.
   PubMed Web of Science ®Google Scholar
• WILLSON TM, NORRIS J D, WAGNER BL, et al.: Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology (1997) 138:3901–3911.
   PubMed Web of Science ®Google Scholar
• BJARNASON K, SKRUMSAGER BK, KIEHR B: Izvorme-loxifene, a new partial estrogen receptor agonist demonstrates antiresorptive and antiatherogenic properties in postmenopausal women. J. Bone Min. Res. (1997) 12:S346.
   Google Scholar
• KAUFFMAN RF, BRYANT HU: Selective estrogen receptor modulators. Drugs News Perspect. (1995) 8:531–538.
   Google Scholar
• ••Good general review on SERMs.
   Google Scholar
• YAMASHITA S, TAKAYANAGI A, SHIMIZU N: Temporal and cell-type specific expression of c-fos and c-jun protooncogenes in the mouse uterus after estrogen stimulation. Endocrinology (1996) 137:5468–5475.
   PubMed Web of Science ®Google Scholar
• LOVE RR, CAMERON L, CONNELL BL, et al.: Symptoms associated with tamoxifen treatment in postmeno-pausal women. Arch. Int. Med. (1991) 151:1842–1847.
   PubMed Web of Science ®Google Scholar
• NORRIS JD, FAN D, WAGNER BL, et al.: Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifene mixed agonist activity. Mol. Endocrinol. (1996) 10:1605–1616.
   PubMed Web of Science ®Google Scholar
• HOCHNER-CELNIKIER D, GREENFIELD C, FINCI-YEHESKEL Z, et al.: Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocar-cinoma cells. Mol. Human Reprod. (1997) 3:1019–1027.
   PubMed Web of Science ®Google Scholar
• NUTTALL ME, BRADBEER JN, STROUP GB, et al.:Idoxifene: a novel selective oestrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. Endocrinology (1 9 9 8) 139:5224-5234.
   Google Scholar
• MCDONNELL DP, CLEMM DL, HERMAN T, et al.: Analysisof estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. (1995) 9:659–669.
   PubMed Web of Science ®Google Scholar
• •Biochemical overview of the ER.
   Google Scholar
• MOSSELMANN S, POLMAN J, DIJKEMA R: ERI3: identifica-tion and characterization of a novel human estrogen receptor. FEBS Lett. (1996) 392:49–53.
   PubMed Web of Science ®Google Scholar
• PAECH K, WEBB P, KUIPER GG, et al.: Differential ligand activation of estrogen receptors ERa and ERI3 at AP-1 sites. Science (1997) 277:1508–1510.
   PubMed Web of Science ®Google Scholar
• RAY NF, CHAN JK, THAMER M, et al.: Medical expendi-tures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner. Res. (1997) 12:24–35.
   PubMed Web of Science ®Google Scholar
• CUMMINGS SR, RUBIN SM, BLACK D: The future of hip fractures in the United States. Numbers, costs and potential effects of postmenopausal estrogen. Clin. Orthop. Rel. Res. (1990) 252:163–166.
   PubMed Web of Science ®Google Scholar
• MELTON LI II: How many women have osteoporosis now J. Bone Miner. Res. (1995) 10:175–177.
   PubMed Web of Science ®Google Scholar
• ••Good overview of epidemiological studies.
   Google Scholar
• MELTON LI III, KAN SH, FRYE MA, et al.: Epidemiology ofvertebral fractures in women. Am. J Epidemiol. (1989) 129:1000–1011.
   PubMed Web of Science ®Google Scholar
• JENSEN GF, CHRISTIANSEN C, BOESEN J, et al.: Epidemi-ology of postmenopausal spinal and long bone fractures. A unifying approach to postmenopausal osteoporosis. Clin. Orthop. Rel. Res. (1982) 166:75–81.
   PubMedGoogle Scholar
• O'NEILL TW, FELSENEBRG D, VARLOW J, et al.: The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J. Bone Miner. Res. (1996) 11:1010–1018.
   PubMed Web of Science ®Google Scholar
• COOPER C, O'NEILL T, SILMAN A: The epidemiology of vertebral fractures. European Vertebral Osteoporosis Study Group. Bone (1993) 1 4 (Suppl. 1):589–597.
   Google Scholar
• SCHUTTE HE: Social and economic impact of osteopo-rosis: a review of the literature. Eur. j Radio]. (1995) 20:165–169.
   PubMed Web of Science ®Google Scholar
• LINDSAY R: The burden of osteoporosis: cost. Am. JMed. (1995) 98 (Suppl. 2A):2A–95.
   Google Scholar
• BARRETT-CONNER E: The economic and human costs of osteoporotic fracture. Am. J Med. (1995) 98 (Suppl. 2A):S3–S8.
   Google Scholar
• MELTON LJ: Flip fractures: a worldwide problem today and tomorrow. Bone (1990) 14:S1–S8.
   Google Scholar
• THE WRITING GROUP FOR THE PEPI TRIAL: Effects ofhormone therapy on bone mineral density: results from the postmenopausal estrogen /progestininterventions (PEP!) trial. j Am. Med. Assoc. (1996) 276:1389–1396.
   PubMed Web of Science ®Google Scholar
• HOSKING D, CHILVERS C, CHRISTIANSEN C, et al.: Preven-tion of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl. J Med. (1998) 338:485–492.
   PubMed Web of Science ®Google Scholar
• MICHAELSSON K, BARON JA, FARAHMAND BA, et al.:Hormone replacement therapy and risk of hip fracture: population based case-control study. Br. Med. J (1998) 316:1858–1863.
   PubMed Web of Science ®Google Scholar
• COMPSTON JE: HRT and osteoporosis. Br. Med. Bull.(1992) 48:309–314.
   PubMed Web of Science ®Google Scholar
• SPEROFF L, ROWAN J, SYMONS J, et al.: The comparativeeffect on bone density, endometrium and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. j Am. Med. Assoc. (1996) 276:1397–1403.
   PubMed Web of Science ®Google Scholar
• HULLEY S, GRADY D, BUSH T, et al.: Randomized trial ofestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J. Am. Med. Assoc. (1998) 280:605–613.
   PubMed Web of Science ®Google Scholar
• BERESFORD SA, WEISS NS, VOIGT LF, et al.: Risk ofendometrial cancer in relation to use of oestrogen combined with cyclic progesterone therapy in postmenopausal women. Lancet (1997) 349:458–461.
   PubMed Web of Science ®Google Scholar
• COLDITZ GA: Hormones and breast cancer: evidenceand implications for consideration of risks and benefits of hormone replacement therapy. j Women's Health (1999) 8:347–57.
   PubMed Web of Science ®Google Scholar
• LOVE RR, MAZESS RB, BARDEN HS, et al.: Effects oftamoxifen on bone mineral density in postmeno-pausal women with breast cancer. N Engl. J. Med. (1992) 326:852–856.
   PubMed Web of Science ®Google Scholar
• DELMAS PD, BJARNASON NH, MITLAK BH, et al.: Effects ofraloxifene on bone mineral density, serum choles-terol concentrations and uterine endometrium in postmenopausal women. N. EngL J. Med. (1997) 337:1641–1647.
   PubMed Web of Science ®Google Scholar
• •In vivo effects of the only SERM on the market.
   Google Scholar
• WALSH BW, KULLER LH, WILD RA, et al.: Effects ofraloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J. Am. Med. Assoc. (1998) 279:1445–1451.
   PubMed Web of Science ®Google Scholar
• ETTINGER B, BLACK DM, MITLAK BH, et al.: Reduction ofvertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investiga-tors. J. Am. Med. Assoc. (1999) 282:637–645.
   PubMed Web of Science ®Google Scholar
• CUMMINGS SR, ECKERT S, KRUEGER KA, et al.: The effectof raloxifene on risk of breast cancer in postmeno-pausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J Am. Med. Assoc. (1999) 281:2189–2197.
   PubMed Web of Science ®Google Scholar
• BEARDSWORTH SA, KEARNEY CE, PURDIE DW: Preven-tion of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two year randomised controlled trial. Br] Obstet. Gynecol. (1999) 106:678–683.
   PubMedGoogle Scholar
• GENAZZANI AR, BENDEK-JASZMANN LJ, HART DM, et al:Org OD 14 and the endometrium. Maturitas (1991) 13:243–251.
   PubMed Web of Science ®Google Scholar
• GOMPEL A, SIROMACHKOVA M, LOMBAT A, et al.: Tibolone actions on normal and breast cancer cells. Eur. J. Cancer (2000) 26 (Suppl. 4):S76–S77.
   Google Scholar
• NUTTALL ME, FISHER PW, SUVA LJ, et al: The selectiveestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific estrogen-response element (ERE)-dep en-dent/independent mechanisms in vitro. Eur. J. Cancer (2000) 36:63–64.
   Google Scholar
• KAUFFMAN RF, BENSCH WR, ROUDEBUSH RE, et al: Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator. J Pharm. Exp. Therap. (1997) 280(0:146–153.
   PubMedGoogle Scholar
• MITLAK BH, COHEN FJ: In search of optimal long-termfemale hormone replacement: the potential of selective estrogen receptor modulators. Horm. Res. (1997) 48:155–163.
   PubMed Web of Science ®Google Scholar
• SATO M, GRESE TA, DODGE JA, et al.: Emerging therapiesfor the prevention or treatment of postmenopausal osteoporosis. J Med. Chem. (1999) 42(1):1–24.
   PubMed Web of Science ®Google Scholar
• ROSATI RL, JARDINE PD, CAMERON KO, et al.: Discoveryand preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med. Chem. (1998) 41:2928–2931.
   PubMed Web of Science ®Google Scholar
• KOMM BS, MILLER CP, LYTTLE CR: WAY-140424, a thirdgeneration tissue selective estrogen with a potentially improved therapeutic profile. J. Bone Miner. Res. (2000) 15 (Suppl. 1):S161.
   Google Scholar
• KE HZ, CHEN HK, SIMMONS HA, et al: Comparative effects of droloxifene, tamoxifen and estrogen on bone, serum cholesterol and uterine histology in the ovariectomized rat model. Bone (1997) 20:31–39.
   PubMed Web of Science ®Google Scholar
• CHESNUT C, WEISS S, MULDER H, et al: Idoxifene increases bone mineral density in osteopenic postmenopausal women. Bone (1998) 23 (5):389.
   Google Scholar
• FLEDELIUS C, HOIBERG SD, VINTERBY A, et al.: Izvorme-loxifene, NNC 45-0320 and NNC 45-0781 prevent bone loss in the ovariectomized rat: a comparative study of peripheral quantitative computed tomography, ash BMD and histomorphometry. Bone (1998) 23 (5):369.
   Google Scholar
• HODSMAN AB, DROST D, FRAHER LJ, et al.: The addition of a raloxifene analog (LY117018) allows for reduced PTH(1-34) dosing during reversal of osteopenia in ovariectomized rats. J. Bone Miner. Res. (1999) 14:675–679.
   PubMed Web of Science ®Google Scholar
• WINTER MA, BELL MG, MUEHL BS, et al: Conformation-ally restricted analogs of raloxifene: idenobenzothio-phenes as selective estrogen receptor modulators.214th American Chemical Society National Meeting (7 Sep 1997) (Poster). MEDI 229.
   Google Scholar
• TSUSHIMA N, HARADA H, KATSUMATA T, et al.: The new bisphosphonate-estrogen hybrid compound has high affinity to the bone and prevents bone loss in OVX rats. J. Bone Miner. Res. (1997) 12(0:168.
   Google Scholar
• AMMANN P, BONJOUR JP, MEYER JM, et al.: The decrease in bone mineral mass and in bone strength induced by ovariectomy in adult rats can be corrected by the new selective estrogen receptor modulator MDL101,986: a comparative study. Bone (1998) 23(5):294.
   Google Scholar